Recent Patents on Development of Nucleic Acid-based Antiviral Drugs Against Seasonal and Pandemic Influenza Virus Infections

PDF

Authors
  1. Saravolac, E.G.
  2. Wong, J.P.
Corporate Authors
Defence R&D Canada - Suffield, Ralston ALTA (CAN)
Abstract
Influenza viruses are etiological agents of deadly flu that continue to pose global health threats, and have caused global pandemics that killed millions of people worldwide. The global crises involving the avian H5N1 influenza provides compelling reasons for accelerate fast track development of novel antiviral drugs against the potential pandemic virus. The availability of neuramindase inhibitors such as oseltamivir (tamiflu) improves our ability to defend against influenza viruses, but the incidences of tamiflu-resistance are on the rapid rise. Nucleic acid-based antivirul drugs are promising classes of experimental antiviral drugs that have been shown in pre-clinical studies to be effective against seasonal and avian influenza scenarios. The review will assess the recent patents, research and development of antisense oligonucleotides, small interfering RNA, immunomodulating RNA for the prevention and treatment of influenza infection.
Report Number
DRDC-SUFFIELD-SL-2009-271 — Scientific Literature
Date of publication
08 Mar 2007
Number of Pages
8
DSTKIM No
CA033076
CANDIS No
532332
Format(s):
Electronic Document(PDF)

Permanent link

Document 1 of 1

Date modified: